Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

Martínez-López, J. (Joaquín); Mateos, M.V. (María Victoria); Encinas, C. (Cristina); Sureda, A. (Anna); Hernández-Rivas, J.Á. (José Ángel); Lopez-de-la-Guía, A. (Ana); Conde, D. (Diego); Krsnik, I. (Isabel); Prieto, E. (Elena); Riaza-Grau, R. (Rosalía); Gironella, M. (Mercedes); Blanchard, M.J. (María Jesús); Caminos, N. (Nerea); Fernández-de-Larrea, C. (Carlos); Senin, M.A. (María Alicia); Escalante, F. (Fernando); de-la-Puerta, J.E. (José Enrique); Giménez, E. (Eugenio); Martínez-Barranco, P. (Pilar); Mateos, J.J. (Juan José); Casado, L.F. (Luis Felipe); Bladé, J. (Joan); Lahuerta, J.J. (Juan José); de-la-Cruz, J. (Javier); San-Miguel, J.F. (Jesús F.)

Keywords:

Enfermedades infecciosas
Mieloma
Pronóstico

Issue Date:

2020

ISSN:

2044-5385

Editorial note:

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Note:

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Citation:

Martínez-López, J. (Joaquín); Mateos, M.V. (María Victoria); Encinas, C. (Cristina); et al. "Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality". Blood Cancer Journal. 10 (103), 2020,

Abstract

There is limited information on the characteristics, prognostic factors, and outcomes of patients with multiple myeloma (MM) hospitalized with COVID-19. This retrospective case series investigated 167 patients reported from 73 hospitals within the Spanish Myeloma Collaborative Group network in March and April, 2020. Outcomes were compared with 167 randomly selected, contemporary, age-/sex-matched noncancer patients with COVID-19 admitted at six participating hospitals. Among MM and noncancer patients, median age was 71 years, and 57% of patients were male; 75 and 77% of patients, respectively, had at least one comorbidity. COVID-19 clinical severity was moderate–severe in 77 and 89% of patients and critical in 8 and 4%, respectively. Supplemental oxygen was required by 47 and 55% of MM and noncancer patients, respectively, and 21%/9% vs 8%/6% required noninvasive/invasive ventilation. Inpatient mortality was 34 and 23% in MM and noncancer patients, respectively. Among MM patients, inpatient mortality was 41% in males, 42% in patients aged >65 years, 49% in patients with active/progressive MM at hospitalization, and 59% in patients with comorbid renal disease at hospitalization, which were independent prognostic factors on adjusted multivariate analysis. This case series demonstrates the increased risk and identifies predictors of inpatient mortality among MM patients hospitalized with COVID-19.

URI:

https://hdl.handle.net/10171/67164

DOI:

10.1038/s41408-020-00372-5

Appears in Collections:

DA - CIMA - Hemato-oncología - Mieloma - Artículos de Revista

Files in This Item: